ADRB3 and hydrops fetalis: Recently, a clinical study investigating the effects of the β3-AR agonist mirabegron in HF patients found that after one week of regimen, mirabegron significantly increased cardiac index and decreased pulmonary vascular resistance in patients with moderate to severe HF with reduced ejection fraction (HFrEF) [73].